Dynamic actuation enhances transport and extends therapeutic lifespan in an implantable drug delivery platform
Date
2022-08-03Author
Whyte, William
Goswami, Debkalpa
Wang, Sophie X.
Fan, Yiling
Ward, Niamh A.
Levey, Ruth E.
Beatty, Rachel
Robinson, Scott T.
Sheppard, Declan
O’Connor, Raymond
Monahan, David S.
Trask, Lesley
Mendez, Keegan L.
Varela, Claudia E.
Horvath, Markus A.
Wylie, Robert
O’Dwyer, Joanne
Domingo-Lopez, Daniel A.
Rothman, Arielle S.
Duffy, Garry P.
Dolan, Eimear B.
Roche, Ellen T.
Metadata
Show full item recordUsage
This item's downloads: 116 (view details)
Cited 1 times in Scopus (view citations)
Recommended Citation
Whyte, William, Goswami, Debkalpa, Wang, Sophie X., Fan, Yiling, Ward, Niamh A., Levey, Ruth E., Beatty, Rachel, Robinson, Scott T., Sheppard, Declan, O’Connor, Raymond, Monahan, David S., Trask, Lesley, Mendez, Keegan L., Varela, Claudia E., Horvath, Markus A., Wylie, Robert, O’Dwyer, Joanne, Domingo-Lopez, Daniel A., Rothman, Arielle S., Duffy, Garry P., Dolan, Eimear B., Roche, Ellen T. (2022). Dynamic actuation enhances transport and extends therapeutic lifespan in an implantable drug delivery platform. Nature Communications, 13(1), 4496. doi:10.1038/s41467-022-32147-w
Published Version
Abstract
Fibrous capsule (FC) formation, secondary to the foreign body response (FBR), impedes molecular transport and is detrimental to the long-term efficacy of implantable drug delivery devices, especially when tunable, temporal control is necessary. We report the development of an implantable mechanotherapeutic drug delivery platform to mitigate and overcome this host immune response using two distinct, yet synergistic soft robotic strategies. Firstly, daily intermittent actuation (cycling at 1¿Hz for 5¿minutes every 12¿hours) preserves long-term, rapid delivery of a model drug (insulin) over 8 weeks of implantation, by mediating local immunomodulation of the cellular FBR and inducing multiphasic temporal FC changes. Secondly, actuation-mediated rapid release of therapy can enhance mass transport and therapeutic effect with tunable, temporal control. In a step towards clinical translation, we utilise a minimally invasive percutaneous approach to implant a scaled-up device in a human cadaveric model. Our soft actuatable platform has potential clinical utility for a variety of indications where transport is affected by fibrosis, such as the management of type 1 diabetes.